|
|||||
|
|
Investigating the relationship between plasma neuropeptide-S levels and clinical depression |
|
| Authors: | Hayriye Baykan Ozgur Baykan Merve Sahin Can Hayrettin Kara Adnan Adil Hismiogullari |
| Affiliation: | 1. Department of Psychiatry, Bal?kesir University Faculty of Medicine, Bal?kesir, Turkey;2. Department of Biochemistry, Bal?kesir Atatürk State Hospital, Bal?kesir, Turkey;3. Department of Psychiatry, Hopa State Hospital, Artvin, Turkey;4. Department of Biochemistry, Bal?kesir University Faculty of Medicine, Bal?kesir, Turkey |
| Abstract: | Purpose: Neuropeptide-S (NPS) is a novel 20-amino acid peptide, mainly expressed in the central nervous system and endocrine tissues. NPS has been linked to anxiety and fear-related behaviors. The association of NPS with depression in a human population has not been previously examined. The aim of the current study was to explore the potential association of NPS with clinical depression and comorbid anxiety. Materials and methods: Seventy-nine patients diagnosed with major depressive disorder and seventy-eight controls were included in the study. The Hamilton Depression Scale (HAM-D) and Hamilton Anxiety Scale (HAM-A) were used to measure depression and anxiety levels, respectively. Venous blood samples were obtained to measure plasma NPS levels. Results: There were no statistically significant differences between the patients and controls in terms of sex, marital status, and smoking status. Plasma NPS levels were also not significantly different between the patients and controls. In patients with major depressive disorder, HAM-A and HAM-D scores were significantly higher than those of controls. No correlation was found between plasma NPS levels and age, body mass index (BMI), median HAM-A scores, and median HAM-D scores. Conclusions: Despite a significantly high level of comorbid anxiety among the patient group, we found no relationship between plasma NPS levels and depressive symptomatology. |
| Keywords: | Neuropeptide-S depression anxiety |
